Complex Journey from Innovation to Patient impact
From Snapshots to Movies
LYMPHOMA TREATMENT AT A CROSSROADS
Long-acting Injectable Formulations
Maximising Patient Engagement in Clinical Trials
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
mRNA Platforms as Diagnostics and Therapeutics for Human Infertility Treatments
Associate Professor, Department of Biology, Khalifa University
Junaid Kashir is an Associate Professor in the Department of Biology at Khalifa University and
has previously chaired multiple researchadministrative committees He has been heavily
involved in multiple programs for training graduate clinical embryology students Dr Kashirs
research aims to develop therapeuticdiagnostic interventions to treat infertility and understand
embryology
Articles
Homeopathic Science
Homeopathy a controversial medical system discovered by a German physician Samuel Hahnemann was first postulated at the end of the th century and mentioned in the first edition of his Organon in In such anecdotal times where theories about the deficiency four bodily fluids theories about corrupted juices were propagating against all odds the beginning of prescientific medical theories were bo...
Research Insights
Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
Ansar A Pathan Clare R Sander Helen A Fletcher Ian Poulton Nicola C Alder Natalie E R Beveridge Kathryn T WhelanAdrian V S Hill Helen McShane Centre for Clinical Vaccinology and Tropical Medicine University of Oxford Churchill Hospita
Case Studies
Labile Biologics - Stable Aqueous Formulation of Recombinant Factor VIII
Challenge All marketed Factor VIII products are lyophilised preparations produced by either recombinant technology or purified from pooled plasma The preparations are typically stabilised by addition of sugars Administration of the lyophilised product is a very complex procedure involving a number
Techno Trends
Air-Cooled Peltier Accessories for Accurate Temperature Control
Many pharmaceutical and life science assays require accurate and constant temperature control in order to acquire meaningful data Moreover kinetic measurements are extremely susceptible to variations in temperature especially over long measurements In order to provide accurate and precise temperature control many researchers have discovered that Peltierbased devices p...
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Biologics at Scale
Surbhi Gupta is an Industry Principal at Frost & Sullivan with extensive experience in global pharmaceutical and biotech market research and consulting. She leads the Personalized Therapeutics program, focusing on next-generation modalities and precision medicine. Her expertise spans market analytics, forecasting, and competitive benchmarking, supporting strategic decision-making for global clients. Recognised as a trusted growth advisor, helping stakeholders navigate disruption, accelerate innovation, and capture transformative growth opportunities across the evolving biopharma landscape.
Covid -19 and Nanoparticles
Ramendra Pati Pandey is an Assistant Professor in the Department of Biotechnology/Microbiology/Biomedical Engineering at the SRM University, Delhi-NCR, Sonepat. He was a FAPESP Post-Doctoral Fellow a very prestigious fellowship of Latin America at the Department of Medicine-InCor/HC-FMUSP, University of Sao Paulo, Brazil.
Deepika has completed here master degree from Department of Biotechnology, Deenbandhu Choturam University and Technology, Sonepat, Haryana, India.
Reshma completed her master's degree from the Royal Global University in Guwahati, Assam, India's department of Biotechnology.
Neehasri holds a master's degree in Zoology from Gauhati University in Guwahati, Assam, India, and has also passed the B.Ed. professional exam.
Marine Biomaterials for Drug Delivery Applications
Macha has six years of experience in research and teaching in the area of biomaterials synthesis and characterisations, drug delivery devices, cell culture and bacterial biofilm. He is also Associate Editor of the Journal of The Australian Ceramic Society and has published more than 14 articles and 6 book chapters.
The Emergence of Organ-on-chips for Diseases Studies and Drug Development
Giuseppe Maruccio is Full Professor at Department of Mathematics and Physics – University of Salento and head of Omnics Research Group which comprises researchers with different backgrounds from physics to life sciences working in cross-disciplinary areas with applications from -onics (electronics, spintronics and magnonics) to -omics technologies (genomics, proteomics and cellomics)
Anna Grazia Monteduro is researcher at Department of Mathematics and Physics - University of Salento in Lecce (Italy) and carries out her research activity within Omnics Research Group in the fields of (i) sensors, lab on chip and organ on chip; (ii) Nanoelectronics, spintronics, nanomagnetism and applied superconductivity.
Silvia Rizzato is researcher at the Department of Mathematics and Physics - University of Salento and carries out her research activity within Omnics Research Group on the development of new devices and processes for sensing and spintronics, including surface acoustic waves devices, electrochemical sensors and colloidal lithography for LSPR sensors.
Giusi Caragnano is a PhD student in Nanotechnologies at the University of Salento - CNR Nanotec and she is part of the Omnics Research Group. Her research activity concerns development of the Organ-on-chip to support the treatment of both chronic and cancerous gastrointestinal diseases
press releasesRead more...
Illumina selected to help bring precision medicine into everyday healthcare in Singapore
Illumina Inc today announced it has been selected to provide wholegenome sequencing services for the SGINSIGHT study a cohort under Phase III of Singapores National Precision Medicine NPM programme Expected to include approximately one in Singapore residents or around individuals
Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies
Brise Pharmaceuticals Co Ltd Brise today provided an update on its exclusive license agreement with AbbVie which the companies entered in Under the terms of the collaboration agreement Brise is responsible for discovery efforts and AbbVie will lead global development and commercialization activitie...
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
Rhythm Pharmaceuticals Inc announced an amendment to the global exclusive license agreement with LG Chem Ltd for bivamelagon an investigational oral smallmolecule melanocortin receptor MCR agonist The Company also announced a fiveyear term loan facility led by KKRs HealthCare
Lonza Signs Agreement to Acquire US CDMO Network from Merck KGaA, Darmstadt, Germany, and Significantly Expands its US Presence
Lonza the worlds leading contract development and manufacturing organization CDMO announced today that it has signed a definitive agreement to acquire five CDMO manufacturing sites in the US from Merck KGaA Darmstadt Germany at a total enterprise valuation in the low to midtripledigit millions
Merck Opens €300 Million Asia-Pacific Bioprocessing Center in Daejeon, South Korea
Merck a leading science and technology company today opened its new AsiaPacific Bioprocessing Production Center in Daejeon South Korea The center represents an investment of more than million the companys largest Life Science investment in AsiaPacific to date
Flagship Pioneering Forms Etcelera to Move Drug Discovery from Probability to Prediction
Flagship Pioneering a scientific innovation engine for transformative platforms and products today announced the formation of Etcelera a company created by the merger of the platforms of Cellarity Cellarity Platform Inc Etiome and Empress Therapeutics to pioneer causal intelligence in human biology...
EventsRead more...
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
LATEST NEWSRead more...
DKSH and The Baker Company Partner to Expand Cell Culture and Microbiology Research
DKSH Business Unit Technology has entered into an exclusive distribution agreement with The Baker Company to make its Baker Ruskinn range of controlledenvironment technologies available to laboratories across Thailand The partnership aims to improve access to equipment used in cell culture tissue c...
Fresenius Enters into Agreement with WuXi Biologics to Expand Biosimilars Pipeline
Fresenius has entered into an exclusive development agreement with WuXi Biologics to expand its biosimilars pipeline and strengthen its biopharmaceutical business The partnership will give Fresenius access to WuXi Biologics capabilities in biologics research development and manufacturing
Edison Scientific Enters into Agreement with Pfizer to Advance Drug Research and Development
Edison Scientific has entered into an agreement with Pfizer to introduce its Edison AI Platform and AI scientist Kosmos across Pfizers biopharmaceutical research and development activities The collaboration will combine Edison Scientifics artificial intelligence AI technology with Pfizers scientific...
Appian and PSI CRO Partner to Advance AI-driven Clinical Trial Operations
Appian and PSI CRO have entered into a strategic partnership to introduce an artificial intelligence AIpowered solution for clinical trial site identification and selection The solution is now live and is designed to automate site selection across different therapeutic areas medical conditions and...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
